Loading...
Market
What will be Livdelzi's market share in PBC treatments by end of 2024?
2
Resolution / Starting Odds
Less than 10% • 25%
10-20% • 25%
20-30% • 25%
More than 30% • 25%
Market analysis reports from reputable sources like IMS Health or EvaluatePharma
Story
Gilead's Livdelzi Gains Accelerated FDA Approval for Primary Biliary Cholangitis
Aug 14, 2024, 06:06 PM
The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Gilead Sciences for its liver disease treatment, Livdelzi (Seladelpar). This approval is specifically for the treatment of primary biliary cholangitis (PBC), an autoimmune liver disease that primarily affects women. The drug, which demonstrated significant improvements in liver disease markers and pruritus, was acquired through Gilead's $4.3 billion buyout of CymaBay Therapeutics earlier this year.
View original story
Similar markets
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than 5,000 • 25%
5,000 to 10,000 • 25%
10,000 to 15,000 • 25%
More than 15,000 • 25%
Yes • 50%
No • 50%
Less than 10% • 25%
10% to 25% • 25%
25% to 50% • 25%
More than 50% • 25%
FDA approval granted • 25%
FDA approval denied • 25%
Further trials required • 25%
Withdrawn by Gilead • 25%
Below 20% • 25%
20% to 40% • 25%
40% to 60% • 25%
Above 60% • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than 20% • 25%
20% to 40% • 25%
40% to 60% • 25%
More than 60% • 25%
<10% • 25%
10-25% • 25%
25-50% • 25%
>50% • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
0-10% • 25%
10-20% • 25%
20-30% • 25%
30% or more • 25%
Less than 10% • 25%
10% to 25% • 25%
25% to 50% • 25%
More than 50% • 25%